We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

41 hedge funds and large institutions have $130M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

0% more funds holding

Funds holding: 41 → 41 (0)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

45% less capital invested

Capital invested by funds: $235M → $130M (-$105M)

Holders
41
Holders Change
–
Holders Change %
0%
% of All Funds
0.65%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
4
Increased
8
Reduced
9
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$794K
2
APM
Avidity Partners Management
Texas
+$262K
3
WP
Woodline Partners
California
+$250K
4
Federated Hermes
Federated Hermes
Pennsylvania
+$160K
5
Morgan Stanley
Morgan Stanley
New York
+$91.2K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.61M
2
GTC
Ghost Tree Capital
New York
-$543K
3
EHI
Eagle Health Investments
Connecticut
-$323K
4
Two Sigma Investments
Two Sigma Investments
New York
-$145K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$107K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$27.8M +$160K +50,000 +0.5%
APM
2
Avidity Partners Management
Texas
$15M +$262K +81,850 +1%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$10.9M -$1.61M -503,609 -11%
JJ
4
Johnson & Johnson
New Jersey
$9.54M – – –
O
5
OrbiMed
New York
$8.12M – – –
Canada Pension Plan Investment Board
6
Canada Pension Plan Investment Board
Ontario, Canada
$8.1M – – –
ASP
7
Adams Street Partners
Illinois
$7.66M – – –
DM
8
Deerfield Management
New York
$7.34M – – –
PA
9
Perceptive Advisors
New York
$7.15M – – –
TGA
10
TPG GP A
Texas
$6.63M – – –
AG
11
Artal Group
Luxembourg
$4.49M – – –
PBPIA
12
Pivotal bioVenture Partners Investment Advisor
California
$4.06M – – –
SFM
13
Sphera Funds Management
Israel
$3.52M +$80.2K +25,000 +2%
1832 Asset Management
14
1832 Asset Management
Ontario, Canada
$1.91M – – –
Millennium Management
15
Millennium Management
New York
$1.51M +$794K +247,552 +74%
EHI
16
Eagle Health Investments
Connecticut
$1.51M -$323K -100,601 -15%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$855K – – –
UOC
18
UBS O'Connor
Illinois
$714K – – –
SCM
19
Sio Capital Management
New York
$640K – – –
GTC
20
Ghost Tree Capital
New York
$633K -$543K -169,412 -41%
Morgan Stanley
21
Morgan Stanley
New York
$432K +$91.2K +28,449 +21%
SI
22
Sofinnova Investments
California
$304K – – –
UBS Group
23
UBS Group
Switzerland
$243K -$2.09K -651 -0.7%
WP
24
Woodline Partners
California
$203K +$250K +78,035 New
SAM
25
Sectoral Asset Management
Quebec, Canada
$149K – – –
1
2

FUSN Hedge Fund Activity: Q3 2023 in Review

41 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q3 2023, worth a combined $130M — down 45% from $235M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new FUSN positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 9 trimmed.

The largest buyer was Millennium Management, adding an estimated $794K. The largest seller was Fidelity Investments, cutting an estimated $1.61M.

  • 41 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $130M of Fusion Pharmaceuticals Inc. Common Shares stock for Q3 2023, down 45% quarter-over-quarter.
  • 4 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q3 2023 and 3 closed out, a net change of +1 holder.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q3 2023 was Millennium Management, an estimated $794K added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q3 2023 was Fidelity Investments, an estimated $1.61M sold.

Based on aggregated 13F filings for Q3 2023.